Analysis of Hepatitis C Virus Resistance-Associated Substitutions in Direct-Acting Antiviral Failure in South Korea Using Next-Generation Sequencing.
Kyung-Ah KimSejoon LeeHye Jung ParkEun Sun JangYoun Jae LeeSung Bum ChoYoung Suk KimIn Hee KimByung Seok LeeWoo Jin ChungSang Hoon AhnSeungtaek KimSook Hyang JeongPublished in: Clinical and molecular hepatology (2023)
NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RAS after failed DAA treatment in genotype 1b. However, RAS was rarely present in patients with genotype 2 treated with sofosbuvir plus ribavirin. Despite baseline or treatment-emergent RAS, retreatment with pan-genotypic DAA was highly successful in Korea, encouraging active retreatment for unsuccessful DAA treatment.